PALISADE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.57 USD | -0.22% |
|
-3.99% | -48.36% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17.65 | 8.016 | 5.47 | 4.289 | - | - |
| Enterprise Value (EV) 1 | 17.65 | 8.016 | 5.47 | 4.289 | 4.289 | 4.289 |
| P/E ratio | -0.45 x | -0.31 x | -0.33 x | -0.39 x | -0.52 x | -0.47 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 21.9 x | - | - | - |
| EV / Revenue | - | - | 21.9 x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 18.1 | 103 | 618 | 936.4 | - | - |
| Reference price 2 | 975.0 | 78.00 | 8.850 | 4.570 | 4.570 | 4.570 |
| Announcement Date | 17/03/22 | 22/03/23 | 26/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.25 | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -41.85 | -15.31 | -13.07 | -14.97 | -20.03 | -23.85 |
| Operating Margin | - | - | -5,228% | - | - | - |
| Earnings before Tax (EBT) 1 | -26.62 | -14.26 | -12.3 | -14.82 | -19.85 | -23.62 |
| Net income 1 | -26.62 | -14.26 | -12.3 | -14.82 | -19.85 | -23.62 |
| Net margin | - | - | -4,920% | - | - | - |
| EPS 2 | -2,145 | -247.9 | -27.00 | -11.66 | -8.810 | -9.650 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 17/03/22 | 22/03/23 | 26/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 0.25 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.027 | -3.888 | -3.572 | -4.003 | -3.848 | -2.529 | -3.609 | -3.778 | -3.154 | -3.673 | -3.698 | -3.765 | -3.832 |
| Operating Margin | - | - | - | - | - | -1,011.6% | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 1.073 | -4.205 | -2.344 | -3.991 | -3.72 | -2.34 | -3.393 | -3.596 | -2.971 | -3.527 | -3.7 | -3.764 | -3.831 |
| Net income 1 | 1.073 | -4.205 | -2.344 | -3.991 | -3.72 | -2.34 | -3.393 | -3.596 | -2.971 | -3.527 | -3.7 | -3.764 | -3.831 |
| Net margin | - | - | - | - | - | -936% | - | - | - | - | - | - | - |
| EPS 2 | 480.0 | -195.0 | -90.00 | -60.00 | -89.85 | -8.100 | -7.950 | -7.350 | -3.750 | -4.590 | -2.930 | -2.480 | -1.980 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 17/03/22 | 13/05/22 | 15/08/22 | 14/11/22 | 22/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 26/03/24 | 13/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 17/03/22 | 22/03/23 | 26/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.57
USD
Average target price
33.75
USD
Spread / Average Target
+638.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.36% | 4.29M | |
| +21.85% | 46.93B | |
| +37.63% | 39.08B | |
| -8.05% | 38.48B | |
| +29.04% | 31.01B | |
| -13.75% | 26.14B | |
| +10.65% | 25.88B | |
| +38.43% | 12.53B | |
| -6.92% | 11.36B | |
| -12.29% | 10.65B |
- Stock Market
- Equities
- SNCA Stock
- Financials Palisade Bio, Inc.
